Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma
NCT05797805 · View on ClinicalTrials.gov ↗
Study Summary
This study will be conducted in 2 parts. The first part is a phase 1 single-agent dose escalation, and dose optimization, study of tegavivint in patients with advanced HCC after failure of at least one line of prior systemic therapy. The second part of the study will begin with a brief dose escalation part for each combination (tegavivint plus cabozantinib or tegavivint plus lenvatinib) followed by a combination dose expansion.
Conditions Studied
Interventions
- DRUG Cabozantinib
- DRUG Lenvatinib
- DRUG Tegavivint
Study Locations (8)
Texas
- UT Southwestern — Dallas
- MD Anderson Cancer Center — Houston
California
- City of Hope — Duarte
Florida
- Sylvester Comprehensive Cancer Center — Miami
Illinois
- University of Chicago — Chicago
North Carolina
- Levine Cancer Institute — Charlotte
Washington
- Fred Hutchinson Cancer Center — Seattle
Ontario
- UHN - Princess Margaret Cancer Centre — Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 178 participants |
| Start Date | 2023-09-13 |
| Est. Completion | 2026-06 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05797805
The ClinicalTrials.gov registry entry for NCT05797805 describes a study currently listed as recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 178 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Iterion Therapeutics, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Advanced Hepatocellular Carcinoma appearing as the primary indexed condition, and to 3 interventions — of which Cabozantinib is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05797805 reports 8 study locations spanning 7 distinct geographic areas — top geographies include Texas, California, Florida. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05797805 about?
NCT05797805 is a clinical study titled "A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma". This study will be conducted in 2 parts. The first part is a phase 1 single-agent dose escalation, and dose optimization, study of tegavivint in patients with advanced HCC after failure of at least one line of prior systemic therapy. The second part of the study will begin with a brief dose escalati...
What is the current status of trial NCT05797805?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 178 participants. The study started on 2023-09-13. Estimated completion is 2026-06.
What conditions does trial NCT05797805 study?
This clinical trial studies the following conditions: Advanced Hepatocellular Carcinoma. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05797805?
The interventions under investigation include: Cabozantinib (DRUG), Lenvatinib (DRUG), Tegavivint (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05797805?
This trial is sponsored by Iterion Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05797805 being conducted?
This trial has 8 study locations across California, Florida, Illinois, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.